Danaher Corporation
$189.21
▼
-2.79%
2026-04-22 10:12:13
www.danaher.com
NYQ: DHR
Explore Danaher Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$133.79 B
Current Price
$189.21
52W High / Low
$242.8 / $180.03
Stock P/E
37.67
Book Value
$74.32
Dividend Yield
0.82%
ROCE
6.12%
ROE
7.05%
Face Value
—
EPS
$5.03
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
58,000
Beta
0.99
Debt / Equity
37.49
Current Ratio
1.87
Quick Ratio
1.51
Forward P/E
20.82
Price / Sales
5.46
Enterprise Value
$149.17 B
EV / EBITDA
19.04
EV / Revenue
6.07
Rating
Strong Buy
Target Price
$262.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Castle Biosciences, Inc. | $25.16 | — | $744.77 M | — | -8.4% | -5.21% | $44.28 / $14.59 | $15.86 |
| 2. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 3. | iSpecimen Inc. | $0.13 | — | $4.05 M | — | -355.55% | -3.28% | $3.18 / $0.1 | $0.31 |
| 4. | FONAR Corporation | $18.8 | 15.61 | $117.93 M | — | 5.81% | 6.01% | $18.86 / $12 | $27.01 |
| 5. | Mainz Biomed N.V. | $0.47 | — | $5.89 M | — | -252.7% | -4.88% | $4.43 / $0.4 | $0.62 |
| 6. | Insight Molecular Diagnostics Inc. | $3.99 | — | $128.35 M | — | -223.51% | 229.65% | $8.51 / $2.33 | $-1.1 |
| 7. | ENDRA Life Sciences Inc. | $6.01 | — | $7.46 M | — | -281.17% | -2.92% | $11.96 / $2.9 | $0.22 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 6.84 B | 6.05 B | 5.94 B | 5.74 B | 6.54 B | — |
| Operating Profit | 1.5 B | 1.15 B | 760 M | 1.27 B | 1.43 B | — |
| Net Profit | 1.2 B | 908 M | 555 M | 954 M | 1.09 B | — |
| EPS in Rs | 1.69 | 1.28 | 0.78 | 1.35 | 1.53 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 24.57 B | 23.88 B | 23.89 B | 26.64 B |
| Operating Profit | 4.69 B | 4.86 B | 5.2 B | 7.54 B |
| Net Profit | 3.61 B | 3.9 B | 4.76 B | 7.21 B |
| EPS in Rs | 5.11 | 5.51 | 6.73 | 10.19 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 83.46 B | 77.54 B | 84.49 B | 84.35 B |
| Total Liabilities | 30.92 B | 27.99 B | 31 B | 34.26 B |
| Equity | 52.53 B | 49.54 B | 53.49 B | 50.08 B |
| Current Assets | 12.76 B | 9.5 B | 13.94 B | 15.88 B |
| Current Liabilities | 6.81 B | 6.8 B | 8.27 B | 8.39 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 6.42 B | 6.69 B | 7.16 B | 8.52 B |
| Investing CF | -1.2 B | -1.98 B | -7.08 B | -2.23 B |
| Financing CF | -2.96 B | -8.38 B | -273 M | -2.57 B |
| Free CF | 5.26 B | 5.3 B | 5.78 B | 7.4 B |
| Capex | -1.16 B | -1.39 B | -1.38 B | -1.12 B |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -0.06% | -10.33% | — | — |
| Earnings Growth % | -18.16% | -33.92% | — | — |
| Profit Margin % | 16.33% | 19.94% | 27.06% | — |
| Operating Margin % | 20.37% | 21.77% | 28.29% | — |
| Gross Margin % | 59.5% | 58.74% | 60.76% | — |
| EBITDA Margin % | 30.48% | 31.38% | 35.59% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-03-27 | $0.4 |
| 2025-12-26 | $0.32 |
| 2025-09-26 | $0.32 |
| 2025-06-27 | $0.32 |
| 2025-03-28 | $0.32 |
Stock Splits
| Date | Split |
|---|---|
| 2023-10-02 | 1:1.128 |